Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) said Friday it’s made some inroads with its financials in 2024, removing its going concern designation as it looks to advance its clinical pipeline for brain disorders and alcohol-related health products.
The company, which rebranded from FSD Pharma in August, posted cash…
Please login to read all 377 words.
